The effect of LRRK2 mutations on the cholinergic system in manifest and premanifest stages of Parkinson's disease: a cross-sectional PET study.

doi:10.1016/S1474-4422(18)30032-2

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

The effect of LRRK2 mutations on the cholinergic system in manifest and premanifest stages of Parkinson's disease: a cross-sectional PET study.

The Lancet. Neurology - 1 Apr 2018

Liu Shu-Ying, Wile Daryl J, Fu Jessie Fanglu, Valerio Jason, Shahinfard Elham, McCormick Siobhan, Mabrouk Rostom, Vafai Nasim, McKenzie Jess, Neilson Nicole, Perez-Soriano Alexandra, Arena Julieta E, Cherkasova Mariya, Chan Piu, Zhang Jing, Zabetian Cyrus P, Aasly Jan O, Wszolek Zbigniew K, McKeown Martin J, Adam Michael J, Ruth Thomas J, Schulzer Michael, Sossi Vesna, Stoessl A Jon

Abstract excerpt

BACKGROUND: Markers of neuroinflammation are increased in some patients with LRRK2 Parkinson's disease compared with individuals with idiopathic Parkinson's disease, suggesting possible differences in disease pathogenesis. Previous PET studies have suggested amplified dopamine turnover and preserved serotonergic innervation in LRRK2 mutation carriers. We postulated that patients with LRRK2 mutations might show...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acetylcholinesterase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Brain

Share to Cholinergic Neurons

Share to Cross-Sectional Studies

Share to Leucine-Rich Repeat Serine-Threonine Protein Kinase-2

Share to Parkinson Disease

Share to Positron-Emission Tomography

Share to Prodromal Symptoms

Source

Open in PubMed Open full text

Identifiers

PMID: 29456161
DOI: 10.1016/S1474-4422(18)30032-2
PMCID: PMC5942215

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The effect of LRRK2 mutations on the cholinergic system in manifest and premanifest stages of Parkinson's disease: a cross-sectional PET study.PMID 29456161Read ↗

Serotonin and dopamine transporter PET changes in the premotor phase of LRRK2 parkinsonism: cross-sectional studies.Semantic proximity Read ↗

Cohort Profile: the Oxford Parkinson’s Disease Centre Discovery Cohort Magnetic Resonance Imaging sub-study (OPDC-MRI)Semantic proximity Read ↗

Increased basal forebrain volumes could prevent cognitive decline in LRRK2 Parkinson's disease.Semantic proximity Read ↗

Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study.Semantic proximity Read ↗

Neuroimaging Biomarkers in Parkinson's Disease: Current Applications and Future DirectionsSemantic proximity Read ↗

A multicenter longitudinal study of cholinergic subgroups in Parkinson diseaseSemantic proximity Read ↗

Central cholinergic degeneration in prodromal and early manifest Parkinsons disease: relation to cognition, clinical phenotype, and future conversionSemantic proximity Read ↗

Disease progression in LRRK2 parkinsonism.Semantic proximity Read ↗

Cholinergic circuit genes in the healthy brain are differentially expressed in regions that exhibit gray matter loss in Parkinson’s diseaseSemantic proximity Read ↗

Deep learning classification of MRI differentiates brain changes in genetic and idiopathic Parkinson’s diseaseSemantic proximity Read ↗

Serum Uric Acid in LRRK2 Related Parkinson's Disease: Longitudinal Data from the PPMI Study.Semantic proximity Read ↗

Clinical and Dopamine Transporter Imaging Characteristics of Leucine Rich Repeat Kinase 2 (LRRK2) and Glucosylceramidase Beta (GBA) Parkinson's Disease Participants in the Parkinson's Progression Markers Initiative: A Cross-Sectional Study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.